{
    "nct_id": "NCT00726726",
    "title": "Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Midazolam, Warfarin, Caffeine, Omeprazole and Dextromethorphan in Healthy Male Subjects by Administration of a Modified Cooperstown Cocktail",
    "status": "COMPLETED",
    "last_update_time": "2008-11-04",
    "description_brief": "The purpose of this study is to determine whether BMS-708163 will effect the pharmacokinetics of the commonly prescribed medicines midazolam, warfarin, caffeine,omeprazole and dextromethorphan",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "BMS-708163 (avagacestat) \u2014 oral gamma\u2011secretase inhibitor (small molecule)"
    ],
    "placebo": [
        "Not specified in the provided description"
    ],
    "explanation_target": [
        "Reason: The trial drug BMS-708163 is intended to alter amyloid-\u03b2 production by inhibiting \u03b3\u2011secretase, i.e., it targets Alzheimer pathology (disease-modifying mechanism) rather than acting as a symptomatic cognitive enhancer or neuropsychiatric treatment. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: I searched for BMS-708163 and found it is known as avagacestat, an oral \u03b3\u2011secretase inhibitor developed for Alzheimer disease; clinical pharmacology and early trials describe decreases in CSF A\u03b2 after dosing. This identifies the intervention as a small-molecule, disease-targeted agent. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Reflect: Classifying this trial as 'disease-targeted small molecule' aligns with the drug being a small\u2011molecule \u03b3\u2011secretase inhibitor aimed at modifying A\u03b2 synthesis (disease pathology). The study title (drug\u2013drug PK interactions using the Cooperstown cocktail) is a Phase 1 interaction study and does not change the mechanism or category. \ue200cite\ue202turn0search6\ue202turn0search2\ue201",
        "Web search results (key sources used): PubMed/Clinical Therapeutics descriptions of BMS\u2011708163 (avagacestat) as a selective \u03b3\u2011secretase inhibitor developed for AD showing effects on plasma/CSF A\u03b2. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search5\ue201",
        "ClinicalTrials summary of the titled interaction study (Effect of Concomitant Administration of BMS\u2011708163 on the Pharmacokinetics of ... Cooperstown Cocktail), confirming the exact trial title and that BMS\u2011708163 was the investigational agent. \ue200cite\ue202turn0search6\ue201",
        "Additional publications and methods papers describing BMS\u2011708163 as a \u03b3\u2011secretase inhibitor and its bioanalytical measurement in plasma/CSF. \ue200cite\ue202turn0search2\ue202turn0search4\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational drug BMS-708163 (avagacestat) is a small\u2011molecule \u03b3\u2011secretase inhibitor developed to reduce production of amyloid\u2011\u03b2 (A\u03b2) by inhibiting \u03b3\u2011secretase-mediated cleavage of APP, i.e., it acts on the amyloid production pathway (disease\u2011modifying mechanism). \ue200cite\ue202turn0search1\ue202turn0search0\ue201",
        "Act: Extracted evidence from the literature and trials: BMS\u2011708163 is explicitly described as avagacestat, an oral \u03b3\u2011secretase inhibitor shown to lower CSF/plasma A\u03b2 in preclinical and human studies and tested in Phase 1/2 AD trials. The trial title provided (a pharmacokinetic interaction study using the Cooperstown cocktail) does not change the biological target. Key sources: pharmacodynamics and first\u2011in\u2011human PK/PD reports and AD trial summaries. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search4\ue202turn0search5\ue201",
        "Reflect: The mechanism (\u03b3\u2011secretase inhibition \u2192 reduced A\u03b2 generation) maps directly to CADRO category A) Amyloid beta. There is no indication this trial targets tau, inflammation, synaptic function, or is purely diagnostic \u2014 nor does the description indicate multiple distinct therapeutic targets, so 'A) Amyloid beta' is the most specific fit. I reviewed additional analytic/method papers confirming the compound identity and central A\u03b2 effects. \ue200cite\ue202turn0search6\ue202turn0search4\ue201",
        "Web search results (key sources used): 1) Multicenter single\u2011ascending dose study describing avagacestat (BMS\u2011708163) PK/PD and A\u03b2 effects. \ue200cite\ue202turn0search0\ue201 2) Pharmacodynamics paper demonstrating selective \u03b3\u2011secretase inhibition and CSF A\u03b2 reductions. \ue200cite\ue202turn0search1\ue201 3) Alzheimer's & Dementia abstracts/papers reporting dose\u2011dependent CSF A\u03b2 reductions and clinical trial findings. \ue200cite\ue202turn0search4\ue202turn0search5\ue201 4) LC\u2011MS/MS methods paper and analytical studies for BMS\u2011708163 supporting its identification in plasma/CSF. \ue200cite\ue202turn0search6\ue201"
    ]
}